VEC Vectura Group Plc

TIDMVEC

RNS Number : 7076N

Vectura Group plc

26 September 2019

Board Change

Chippenham, UK - 26 September 2019: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") announces that Dr Susan Foden is stepping down from the Board and her role as Senior Independent Non-Executive Director of Vectura. This change takes effect on 30 September 2019.

Dr Foden is the longest current serving Director of the Group, having been a Board member since 2007. Currently a member of the Nomination Committee, she has also chaired the Group's Remuneration Committee and has been a member of the Audit Committee.

Dr Thomas Werner will replace Dr Foden as Senior Independent Non-Executive Director.

Bruno Angelici, Chairman of the Board, said: "I would like to recognise Susan's significant contributions to Vectura and thank her for her commitment to the Group over the past 12 years. She has provided valuable insight and expertise in her roles across the Board and our Committees. We all wish her every success for the future."

- Ends-

For more information, please contact:

Vectura Group plc

   David Ginivan - VP Corporate Communications                   +44 (0)7471 352 720 
   Elizabeth Knowles - VP Investor Relations                             +44 (0)7767 160 565 

Consilium Strategic Communications

   Mary-Jane Elliott / Sue Stuart / David Daley                         +44 (0)20 3709 5700 

Notes

About Vectura

Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAEAFNSALPNEAF

(END) Dow Jones Newswires

September 26, 2019 04:00 ET (08:00 GMT)

Grafico Azioni Vectura (LSE:VEC)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Vectura (LSE:VEC)
Storico
Da Apr 2023 a Apr 2024